

Ceremony to lay the First Stone of the plant expansion of sterile injectable medicines of Reig Jofre

- The Mayor of Sant Joan Despí, Antoni Poveda, presided the laying of the first stone for the expansion of the sterile injectable pharmaceutical products plant
- After investing 30 million euros, the plant will become the largest lyophilization center, equipped with isolator technology, in Spain and one of the largest in Europe

Barcelona (Spain), January 11, 2019. The Mayor of Sant Joan Despí (municipality of Barcelona), **Antoni Poveda**, presided this morning the laying of the First Stone that will officially start the expansion works of the Reig Jofre plant specialized in the manufacture of sterile injectable products. The ceremony was also attended by Belén García, First Deputy Mayor and Cristian Rastrojo, Councilor for Economic Promotion, Employment and Commerce.

During the ceremony, **Dr. Enric Jo**, Member of the Royal Academy of Pharmacy of Catalonia, director of the plant and recognized expert in freeze-drying technology, explained the expansion project, by which the plant in Barcelona will have the largest lyophilization center, equipped with isolator technology, in Spain and one of the largest in Europe.

A new state-of-the-art building will be built, equipped with 3 large freeze dryers on an area of 2,500 square meters. The new facilities will triple the current production capacity to reach 50 million lyophilized vials, at full capacity. The new plant will be endowed with automated processes in which the product is isolated from human contact to avoid any risk of contamination and will comply with the current health authorities requirements of any country in the world. It will also place Reig Jofre quality standards at efficacy and safety levels comparable to the most advanced international pharmaceutical companies. Moreover, it will also allow the development and manufacture of innovative products of either chemical or biological origin, as well as biosimilar products, and the creation of highly qualified employment.

Ignasi Biosca, CEO of the company, highlighted that, following the competition of the investment plan begun in mid-2018 of 30 million euros in Sant Joan Despí, Reig Jofre will address the entry into markets of enormous complexity and regulatory requirements, as well as of great volumes like the United States, Indonesia, Korea and Japan among others, and is expected to increase exports significantly, besides consolidating current markets of Europe.



With the aim of contributing to a cleaner and more sustainable economy, Reig Jofre will improve energy efficiency in the lyophilization process thanks to financial support of 1.5 million euros from the European Regional Development Fund (ERDF). This project is part of the energy saving and efficiency aid line, co-financed by the ERDF and managed by the Institute for Energy Diversification and Saving (IDAE) under the National Energy Efficiency Fund.

Reig Jofre is recognized since 2014 by the **Profarma** Program of the Ministry of Industry, Commerce and Tourism, for the promotion of competitiveness in the Pharmaceutical Industry, with the qualification of Very Good within Group A.

The pharmaceutical firm maintains a policy of strong commitment to innovation and research by collaborating with start-ups Biotech of Catalonia industrial network and boosting the sector from CataloniaBio and the Biocat Board.

Reig Jofre employs around 1000 people worldwide, thanks to its investment and innovative efforts in the development of new specialties and in the internationalization as one of its pillars of growth, with more than 400 employees in Catalonia, which 340 are in the Sant Joan Despí plant.

Ignasi Biosca said: *"this investment is part of the Reig Jofre commitment with the creation of industrial network and we are very proud to contribute to the generation of highly qualified employment in Catalonia, we expect to have up to 100 new collaborators, when the plant be at full capacity, increase exports and provide services to society, offering essential injectable and lyophilized medicines, manufactured in this plant of Sant Joan Despí and intended to improve the health of millions of patients on five continents."*

The mayor of Sant Joan Despí, Antoni Poveda, for his part, declared *"the importance for the city of the business commitment that Reig Jofre has always had for its facilities in the municipality. A commitment to the future and an international dimension that helps generate quality employment and economic activity associated with research and development."*

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company focused on the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre directs its R&D to the development of new formulations and indications in the therapeutic areas of (dermatology, respiratory/ENT, gynecology); to the development of innovative molecules in collaboration with research start-ups or knowledge centers in either the technological specialization areas of (injectable



products and beta-lactam antibiotics) or the therapeutic areas; and to the development of generic medicines of technological specialization. Reig Jofre has over 900 employees, 4 development and manufacturing centers in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and over 130 commercial partners in 67 countries worldwide. The company reached sales of €168 M in 2017. Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 65,050,067 shares

For further information

Inma Santa-Pau - Head of Communication and Institutional Relations
Tel. (+34) 93 480 67 10 (ext. 1242) - inma.santapau@reigjofre.com